[
  {
    "title": "普瑞眼科(301239.SZ)：拟使用部分超募资金6742万元新建上海普瑞宝视眼科医院项目",
    "href": "http://stock.jrj.com.cn/2022/11/28205837172318.shtml",
    "datetime": "2022-11-28 20:58:02",
    "code": "002399"
  },
  {
    "title": "海普瑞2022年前三季度净利6.52亿同比增长41.33% 汇兑收益同比增加",
    "href": "http://stock.jrj.com.cn/2022/10/28203237095407.shtml",
    "datetime": "2022-10-28 20:32:56",
    "code": "002399"
  },
  {
    "title": "海普瑞(002399.SZ)：前三季度净利6.52亿元，同比增长41.33%",
    "href": "http://stock.jrj.com.cn/2022/10/28163737094011.shtml",
    "datetime": "2022-10-28 16:37:32",
    "code": "002399"
  },
  {
    "title": "普瑞眼科(301239.SZ)：拟使用部分超募资金3385万元新建上海普瑞尚视眼科医院项目",
    "href": "http://stock.jrj.com.cn/2022/10/18211737065266.shtml",
    "datetime": "2022-10-18 21:17:11",
    "code": "002399"
  },
  {
    "title": "海普瑞：拟面向专业投资者公开发行公司债券募资不超10亿元",
    "href": "http://stock.jrj.com.cn/2022/09/30192637034983.shtml",
    "datetime": "2022-09-30 19:26:42",
    "code": "002399"
  },
  {
    "title": "海普瑞(002399.SZ)：拟面向专业投资者公开发行不超10亿元公司债券",
    "href": "http://stock.jrj.com.cn/2022/09/30191537034968.shtml",
    "datetime": "2022-09-30 19:15:02",
    "code": "002399"
  },
  {
    "title": "从一份A级财报看海普瑞（002399.SZ/9989.HK）底部反转信号",
    "href": "http://stock.jrj.com.cn/2022/09/07082236978846.shtml",
    "datetime": "2022-09-07 08:22:21",
    "code": "002399"
  },
  {
    "title": "【互动】海普瑞：上半年公司在欧洲市场的制剂销售均价（以原币计价）同比有所提升",
    "href": "http://stock.jrj.com.cn/2022/09/02164136968198.shtml",
    "datetime": "2022-09-02 16:41:40",
    "code": "002399"
  },
  {
    "title": "海普瑞2022年上半年归属母公司净利润5.11亿元，同比增长51.15%",
    "href": "http://stock.jrj.com.cn/2022/08/30174136953381.shtml",
    "datetime": "2022-08-30 17:41:44",
    "code": "002399"
  },
  {
    "title": "海普瑞(9989.HK)业绩稳健营收净利润双增长 上半年归母净利同比增51.2%",
    "href": "http://stock.jrj.com.cn/2022/08/29184336948402.shtml",
    "datetime": "2022-08-29 18:43:10",
    "code": "002399"
  },
  {
    "title": "海普瑞(09989.HK)拟8月29日举行董事会会议审批中期业绩",
    "href": "http://stock.jrj.com.cn/2022/08/15164836900507.shtml",
    "datetime": "2022-08-15 16:48:32",
    "code": "002399"
  },
  {
    "title": "海普瑞(002399.SZ)2021年年度权益分派10派0.35元 股权登记日7月27日",
    "href": "http://stock.jrj.com.cn/2022/07/20183836829355.shtml",
    "datetime": "2022-07-20 18:38:57",
    "code": "002399"
  },
  {
    "title": "底部大反转！海普瑞（002399.SZ/9989.HK）的资质究竟如何？",
    "href": "http://stock.jrj.com.cn/2022/07/18094136819994.shtml",
    "datetime": "2022-07-18 09:41:30",
    "code": "002399"
  },
  {
    "title": "海普瑞(09989.HK)盈喜：预计上半年净利上升40.02%–60.28%",
    "href": "http://stock.jrj.com.cn/2022/07/13163936807554.shtml",
    "datetime": "2022-07-13 16:39:00",
    "code": "002399"
  },
  {
    "title": "大摩：予海普瑞“增持”评级，目标价上调至12.7港元",
    "href": "http://stock.jrj.com.cn/2022/06/27134236760761.shtml",
    "datetime": "2022-06-27 13:42:27",
    "code": "002399"
  },
  {
    "title": "海普瑞：肝素全球龙头短期利差扩大，长期积极拓宽大分子CDMO+创新药领域",
    "href": "http://stock.jrj.com.cn/hotstock/2022/06/13075236722531.shtml",
    "datetime": "2022-06-13 07:52:34",
    "code": "002399"
  },
  {
    "title": "营收净利双增长，海普瑞（002399.SZ/9989.HK）一季报惊喜不断",
    "href": "http://stock.jrj.com.cn/2022/05/05083636565812.shtml",
    "datetime": "2022-05-05 08:36:12",
    "code": "002399"
  },
  {
    "title": "三大板块协同增长，海普瑞（002399.SZ/9989.HK）投资价值凸显",
    "href": "http://stock.jrj.com.cn/2022/04/12162936315544.shtml",
    "datetime": "2022-04-12 16:29:45",
    "code": "002399"
  },
  {
    "title": "海普瑞更正2021年度报告及摘要：集团实现营业收入和净利润有误",
    "href": "http://stock.jrj.com.cn/2022/04/12141036314237.shtml",
    "datetime": "2022-04-12 14:10:33",
    "code": "002399"
  },
  {
    "title": "海普瑞2021年归属上市公司股东净利润同比下降76.49%",
    "href": "http://stock.jrj.com.cn/2022/04/12115036313693.shtml",
    "datetime": "2022-04-12 11:50:52",
    "code": "002399"
  },
  {
    "title": "海普瑞2021年净利2.41亿同比下滑76.49% 董事长李锂薪酬288.76万",
    "href": "http://stock.jrj.com.cn/2022/04/12051236311593.shtml",
    "datetime": "2022-04-12 05:12:18",
    "code": "002399"
  },
  {
    "title": "海普瑞(002399.SZ)：拟使用不超20亿元自有资金进行现金管理及购买低风险理财产品",
    "href": "http://stock.jrj.com.cn/2022/04/11221736309311.shtml",
    "datetime": "2022-04-11 22:17:05",
    "code": "002399"
  },
  {
    "title": "海普瑞(002399.SZ)2021年度实现营收63.65亿元 同比增长19.38%",
    "href": "http://stock.jrj.com.cn/2022/04/11221436309312.shtml",
    "datetime": "2022-04-11 22:14:24",
    "code": "002399"
  },
  {
    "title": "海普瑞(002399.SZ)：5亿元公司债4月11日起挂牌深交所",
    "href": "http://stock.jrj.com.cn/2022/04/08174636273203.shtml",
    "datetime": "2022-04-08 17:46:27",
    "code": "002399"
  },
  {
    "title": "海普瑞2021年净利3.83亿 较上年同期下滑62.65%",
    "href": "http://stock.jrj.com.cn/2022/03/31141036237666.shtml",
    "datetime": "2022-03-31 14:10:46",
    "code": "002399"
  },
  {
    "title": "海普瑞(002399.SZ)业绩快报：2021年度营收达64.28亿元 同比增长20.56%",
    "href": "http://stock.jrj.com.cn/2022/03/30204436205812.shtml",
    "datetime": "2022-03-30 20:44:16",
    "code": "002399"
  },
  {
    "title": "海普瑞(002399.SZ)：公开发行公司债券注册获证监会批复",
    "href": "http://stock.jrj.com.cn/2022/03/25173535120916.shtml",
    "datetime": "2022-03-25 17:35:28",
    "code": "002399"
  },
  {
    "title": "港股异动 | 海普瑞高开7% 肝素钠原料药及依诺肝素钠原料药获印度批准",
    "href": "http://stock.jrj.com.cn/2022/03/16092434832452.shtml",
    "datetime": "2022-03-16 09:24:11",
    "code": "002399"
  },
  {
    "title": "海普瑞宣布旗下肝素钠和依诺肝素钠原料药于印度获批并实现商业销售",
    "href": "http://stock.jrj.com.cn/2022/03/15173834829861.shtml",
    "datetime": "2022-03-15 17:38:57",
    "code": "002399"
  },
  {
    "title": "海普瑞2021年预计净利2.75亿-4.13亿同比下降73.14%-59.72% 原材料价格呈现下降",
    "href": "http://stock.jrj.com.cn/2022/01/29203134257893.shtml",
    "datetime": "2022-01-29 20:31:50",
    "code": "002399"
  },
  {
    "title": "海普瑞(09989.HK)于美国推出肝素纳注射液",
    "href": "http://stock.jrj.com.cn/2022/01/27164334230695.shtml",
    "datetime": "2022-01-27 16:43:08",
    "code": "002399"
  },
  {
    "title": "海普瑞(002399.SZ)：以H股募集资金1.05亿美元以逐层增资方式向全资子公司香港天道增资",
    "href": "http://stock.jrj.com.cn/2021/12/10194133995754.shtml",
    "datetime": "2021-12-10 19:41:37",
    "code": "002399"
  },
  {
    "title": "海普瑞(09989.HK)：“16海普瑞”将于11月8日兑付及摘牌",
    "href": "http://stock.jrj.com.cn/2021/11/03171433808954.shtml",
    "datetime": "2021-11-03 17:14:43",
    "code": "002399"
  },
  {
    "title": "海普瑞前三财季净利4.62亿元，同比下降34.87%",
    "href": "http://stock.jrj.com.cn/2021/10/28174633770339.shtml",
    "datetime": "2021-10-28 17:46:22",
    "code": "002399"
  },
  {
    "title": "海普瑞(002399.SZ)：第三季度扣非净利润升21.40%至1.23亿元",
    "href": "http://stock.jrj.com.cn/2021/10/27203033764046.shtml",
    "datetime": "2021-10-27 20:30:25",
    "code": "002399"
  },
  {
    "title": "海普瑞(002399.SZ)：拟与正中产控签署南山区高新北海普瑞片区城市更新单元合作开发协议",
    "href": "http://stock.jrj.com.cn/2021/10/15212833700466.shtml",
    "datetime": "2021-10-15 21:28:29",
    "code": "002399"
  },
  {
    "title": "海普瑞发财报股价跌6.53% 上半年净利大降4成",
    "href": "http://stock.jrj.com.cn/2021/08/27175033334371.shtml",
    "datetime": "2021-08-27 17:50:00",
    "code": "002399"
  },
  {
    "title": "海普瑞2021年半年度净利3.38亿元 同比净利减少41.80%",
    "href": "http://stock.jrj.com.cn/2021/08/26232533327820.shtml",
    "datetime": "2021-08-26 23:25:40",
    "code": "002399"
  },
  {
    "title": "海普瑞(002399.SZ)半年度实现营收31.14亿元 同比增长17.09%",
    "href": "http://stock.jrj.com.cn/2021/08/26214033327160.shtml",
    "datetime": "2021-08-26 21:40:23",
    "code": "002399"
  },
  {
    "title": "海普瑞(002399.SZ)：已向河南省慈善总会捐赠100万元支持抗洪抢险救灾",
    "href": "http://stock.jrj.com.cn/2021/07/23165033140739.shtml",
    "datetime": "2021-07-23 16:50:47",
    "code": "002399"
  },
  {
    "title": "海普瑞(002399.SZ)2020年度A股权益分派10派1.5元 股权登记日为7月5日",
    "href": "http://stock.jrj.com.cn/2021/06/28193433011472.shtml",
    "datetime": "2021-06-28 19:34:36",
    "code": "002399"
  },
  {
    "title": "海普瑞(09989.HK)A股拟10派1.5元 股权登记日7月5日",
    "href": "http://stock.jrj.com.cn/2021/06/28190933011386.shtml",
    "datetime": "2021-06-28 19:09:31",
    "code": "002399"
  },
  {
    "title": "海普瑞：目前依诺肝素钠制剂国家级集中采购尚未开展",
    "href": "http://stock.jrj.com.cn/2021/06/18192332956156.shtml",
    "datetime": "2021-06-18 19:23:39",
    "code": "002399"
  },
  {
    "title": "海普瑞：公司2020年度分红派息将于近日实施",
    "href": "http://stock.jrj.com.cn/2021/06/18190532956082.shtml",
    "datetime": "2021-06-18 19:05:49",
    "code": "002399"
  },
  {
    "title": "海普瑞：Curemark正在进行提交FDA审核的准备工作",
    "href": "http://stock.jrj.com.cn/2021/06/18153332954651.shtml",
    "datetime": "2021-06-18 15:33:11",
    "code": "002399"
  },
  {
    "title": "海普瑞：公司的伊诺肝素制剂治疗新冠肺炎在意大利的临床试验在有序推进中",
    "href": "http://stock.jrj.com.cn/2021/06/18152332954601.shtml",
    "datetime": "2021-06-18 15:23:44",
    "code": "002399"
  },
  {
    "title": "海普瑞：公司原副董事长和董事离职相关工作已完成交接",
    "href": "http://stock.jrj.com.cn/2021/06/18152332954600.shtml",
    "datetime": "2021-06-18 15:23:07",
    "code": "002399"
  },
  {
    "title": "海普瑞：赛湾生物近年新增pDNA生产设施 可以为客户提供3个等级pDNA生产和检测服务",
    "href": "http://stock.jrj.com.cn/2021/06/15160232934666.shtml",
    "datetime": "2021-06-15 16:02:10",
    "code": "002399"
  },
  {
    "title": "海普瑞：肝素原料药采取空运 依诺肝素制剂采取海运",
    "href": "http://stock.jrj.com.cn/2021/06/11201332913627.shtml",
    "datetime": "2021-06-11 20:13:39",
    "code": "002399"
  },
  {
    "title": "海普瑞(09989.HK)：INHIX A取得波斯尼亚和黑塞哥维那批准",
    "href": "http://stock.jrj.com.cn/2021/06/10163232905437.shtml",
    "datetime": "2021-06-10 16:32:33",
    "code": "002399"
  },
  {
    "title": "海普瑞：海普瑞作为Curemark的合作伙伴 双方具有畅通的沟通和交流渠道",
    "href": "http://stock.jrj.com.cn/2021/06/08203432895464.shtml",
    "datetime": "2021-06-08 20:34:11",
    "code": "002399"
  },
  {
    "title": "海普瑞：枫海资本以获得中长期投资收益为目标 所选投资标的包括筹建期、运营期等不同阶段的医药行业企业",
    "href": "http://stock.jrj.com.cn/2021/06/08203232895459.shtml",
    "datetime": "2021-06-08 20:32:46",
    "code": "002399"
  },
  {
    "title": "海普瑞：公司目前拥有的相关权益是向Curemark销售原料药和参与其利润分配",
    "href": "http://stock.jrj.com.cn/2021/06/08202932895451.shtml",
    "datetime": "2021-06-08 20:29:13",
    "code": "002399"
  },
  {
    "title": "海普瑞：Curemark正在进行提交FDA审核的准备工作",
    "href": "http://stock.jrj.com.cn/2021/06/08201232895358.shtml",
    "datetime": "2021-06-08 20:12:05",
    "code": "002399"
  },
  {
    "title": "海普瑞：公司目前未直接或间接持有Liminal BioSciences（NASDAQ:LMNL）股票",
    "href": "http://stock.jrj.com.cn/2021/06/08165132893929.shtml",
    "datetime": "2021-06-08 16:51:13",
    "code": "002399"
  },
  {
    "title": "港股异动丨海普瑞(9989.HK)涨4.74% 控股子公司收药物临床试验补充申请批准通知书",
    "href": "http://stock.jrj.com.cn/2021/06/02110532861971.shtml",
    "datetime": "2021-06-02 11:05:19",
    "code": "002399"
  },
  {
    "title": "海普瑞(002399.SZ)：单抗AR-301三期药品临床试验补充申请获批",
    "href": "http://stock.jrj.com.cn/2021/06/01184132858369.shtml",
    "datetime": "2021-06-01 18:41:21",
    "code": "002399"
  },
  {
    "title": "海普瑞：公司多年来打造了强大的肝素全产业链进一步巩固公司在依诺制剂全球市场的领先地位",
    "href": "http://stock.jrj.com.cn/2021/06/01163432857157.shtml",
    "datetime": "2021-06-01 16:34:06",
    "code": "002399"
  },
  {
    "title": "海普瑞：海普瑞对参股企业上海泰沂实行权益法核算 后者的投资损益影响公司的投资收益",
    "href": "http://stock.jrj.com.cn/2021/06/01163232857141.shtml",
    "datetime": "2021-06-01 16:32:42",
    "code": "002399"
  },
  {
    "title": "海普瑞：目前公司产品价格未受到重大影响",
    "href": "http://stock.jrj.com.cn/2021/06/01163132857135.shtml",
    "datetime": "2021-06-01 16:31:04",
    "code": "002399"
  },
  {
    "title": "海普瑞：天道医药已获准成为美国市场已上市依诺肝素钠制剂企业的供应商",
    "href": "http://stock.jrj.com.cn/2021/06/01162732857103.shtml",
    "datetime": "2021-06-01 16:27:22",
    "code": "002399"
  },
  {
    "title": "海普瑞(002399.SZ)：孙暄增持H股计划完成 累计增持64.35万股H股",
    "href": "http://stock.jrj.com.cn/2021/05/18171532776738.shtml",
    "datetime": "2021-05-18 17:15:28",
    "code": "002399"
  },
  {
    "title": "海普瑞：目公司的制剂以海外销售为主 在销售市场、商业模式、费用构成不同的情况下 毛利率的横向可比性不高",
    "href": "http://stock.jrj.com.cn/2021/05/14190632756738.shtml",
    "datetime": "2021-05-14 19:06:21",
    "code": "002399"
  },
  {
    "title": "海普瑞：Curemark将根据FDA的有关要求申报BLA 目前暂未涉及新的临床试验",
    "href": "http://stock.jrj.com.cn/2021/05/14162032755459.shtml",
    "datetime": "2021-05-14 16:20:02",
    "code": "002399"
  },
  {
    "title": "海普瑞(002399.SZ)：基于对公司未来发展的信心、价值的认可 孙暄拟增持H股不低于64.3万股",
    "href": "http://stock.jrj.com.cn/2021/05/06172132702043.shtml",
    "datetime": "2021-05-06 17:21:38",
    "code": "002399"
  },
  {
    "title": "海普瑞：海普瑞有信心实现依诺制剂在全球的经营目标",
    "href": "http://stock.jrj.com.cn/2021/04/30153132487234.shtml",
    "datetime": "2021-04-30 15:31:36",
    "code": "002399"
  },
  {
    "title": "海普瑞(09989.HK)：建议委任张斌先生为执行董事",
    "href": "http://stock.jrj.com.cn/2021/04/20061732405252.shtml",
    "datetime": "2021-04-20 06:17:05",
    "code": "002399"
  },
  {
    "title": "海普瑞：肝素现在已经开始用于预防和治疗易栓症导致的产科并发症",
    "href": "http://stock.jrj.com.cn/2021/04/16152332386461.shtml",
    "datetime": "2021-04-16 15:23:55",
    "code": "002399"
  },
  {
    "title": "海普瑞：公司根据销售模式和物流安排选择出口报关地包括广东和其他地区",
    "href": "http://stock.jrj.com.cn/2021/04/16152332386456.shtml",
    "datetime": "2021-04-16 15:23:43",
    "code": "002399"
  },
  {
    "title": "海普瑞：天道医药已在2020年四季度实现对美国的依诺制剂发货",
    "href": "http://stock.jrj.com.cn/2021/04/13170332365617.shtml",
    "datetime": "2021-04-13 17:03:40",
    "code": "002399"
  },
  {
    "title": "海普瑞(002399.SZ/9989.HK)扣非净利润增长32.74%，估值有望提升",
    "href": "http://stock.jrj.com.cn/2021/04/09075932338646.shtml",
    "datetime": "2021-04-09 07:59:48",
    "code": "002399"
  },
  {
    "title": "海普瑞：对Kymab股权的公允价值评估参考了2021年1月Sanofi全资子公司收购Kymab股权的定价",
    "href": "http://stock.jrj.com.cn/2021/04/02180732271487.shtml",
    "datetime": "2021-04-02 18:07:05",
    "code": "002399"
  },
  {
    "title": "海普瑞：公司与扬州市伊恩生物科技有限公司协商的还款计划目前在执行过程中",
    "href": "http://stock.jrj.com.cn/2021/04/02175732271374.shtml",
    "datetime": "2021-04-02 17:57:53",
    "code": "002399"
  },
  {
    "title": "海普瑞：朋和沙河社区工程项目公司正常使用中",
    "href": "http://stock.jrj.com.cn/2021/04/02175732271363.shtml",
    "datetime": "2021-04-02 17:57:33",
    "code": "002399"
  },
  {
    "title": "海普瑞：为Curemark创新药供应的原料计入CDMO业务收入",
    "href": "http://stock.jrj.com.cn/2021/04/02175732271371.shtml",
    "datetime": "2021-04-02 17:57:05",
    "code": "002399"
  },
  {
    "title": "海普瑞：公司目前持有Curemark的股权比例为3.51%",
    "href": "http://stock.jrj.com.cn/2021/04/02175632271369.shtml",
    "datetime": "2021-04-02 17:56:57",
    "code": "002399"
  },
  {
    "title": "海普瑞：RVX 2020年净利润主要来自其发行的融资工具的公允价值变动",
    "href": "http://stock.jrj.com.cn/2021/04/02175632271372.shtml",
    "datetime": "2021-04-02 17:56:49",
    "code": "002399"
  },
  {
    "title": "海普瑞：Curemark正在进行提交BLA的准备工作",
    "href": "http://stock.jrj.com.cn/2021/04/02175632271368.shtml",
    "datetime": "2021-04-02 17:56:38",
    "code": "002399"
  },
  {
    "title": "海普瑞：公司的库存商品主要包括制剂及API",
    "href": "http://stock.jrj.com.cn/2021/04/02175032271330.shtml",
    "datetime": "2021-04-02 17:50:08",
    "code": "002399"
  },
  {
    "title": "海普瑞去年净利降3% 四季度融通基金华夏基金减持",
    "href": "http://stock.jrj.com.cn/2021/03/30174032248656.shtml",
    "datetime": "2021-03-30 17:40:00",
    "code": "002399"
  },
  {
    "title": "海普瑞2020年净利同比减少3.32% 董事长李锂薪酬449.98万",
    "href": "http://stock.jrj.com.cn/2021/03/30151432247867.shtml",
    "datetime": "2021-03-30 15:14:08",
    "code": "002399"
  },
  {
    "title": "海普瑞(002399.SZ)2020年净利达10.24亿元 拟10派1.5元",
    "href": "http://stock.jrj.com.cn/2021/03/29233632243949.shtml",
    "datetime": "2021-03-29 23:36:13",
    "code": "002399"
  },
  {
    "title": "海普瑞(09989.HK)拟使用部分闲置H股募集资金购买理财产品及进行现金管理",
    "href": "http://stock.jrj.com.cn/2021/03/29225032243810.shtml",
    "datetime": "2021-03-29 22:50:48",
    "code": "002399"
  },
  {
    "title": "海普瑞：海普瑞现金状况良好",
    "href": "http://stock.jrj.com.cn/2021/03/22122532192081.shtml",
    "datetime": "2021-03-22 12:25:56",
    "code": "002399"
  },
  {
    "title": "海普瑞(09989.HK)：“20海普瑞”将于3月1日付息",
    "href": "http://stock.jrj.com.cn/2021/02/23191332013806.shtml",
    "datetime": "2021-02-23 19:13:57",
    "code": "002399"
  },
  {
    "title": "海普瑞：公司依诺肝素治疗新冠病症的研究试验还在进行中",
    "href": "http://stock.jrj.com.cn/2021/01/26175931778645.shtml",
    "datetime": "2021-01-26 17:59:52",
    "code": "002399"
  },
  {
    "title": "海普瑞股价5个月跌4成 其间中信证券发4份研报喊买入",
    "href": "http://stock.jrj.com.cn/2021/01/12175531677444.shtml",
    "datetime": "2021-01-12 17:55:00",
    "code": "002399"
  },
  {
    "title": "海普瑞(002399.SZ)参股公司Kymab获药企巨头赛诺菲收购 彰显新药投资战略眼光",
    "href": "http://stock.jrj.com.cn/2021/01/11200131671967.shtml",
    "datetime": "2021-01-11 20:01:57",
    "code": "002399"
  },
  {
    "title": "海普瑞：公司依诺肝素钠制剂向美国供货业务正在按计划推进",
    "href": "http://stock.jrj.com.cn/2020/12/22165831545997.shtml",
    "datetime": "2020-12-22 16:58:08",
    "code": "002399"
  },
  {
    "title": "海普瑞(002399.SZ)：依诺肝素钠注射液取得加拿大卫生部批准",
    "href": "http://stock.jrj.com.cn/2020/12/09223831451872.shtml",
    "datetime": "2020-12-09 22:38:56",
    "code": "002399"
  },
  {
    "title": "海普瑞：在美国、欧盟布局了原材料采购、肝素及胰酶原料药生产、制剂销售、CDMO及创新药研发业务",
    "href": "http://stock.jrj.com.cn/2020/12/09132031448166.shtml",
    "datetime": "2020-12-09 13:20:23",
    "code": "002399"
  },
  {
    "title": "三十风云人与事之2010年：做空降临融资融券股指期货登场 148元新股海普瑞创纪录 黄光裕狱中打响国美争夺战",
    "href": "http://stock.jrj.com.cn/2020/12/09112331447509.shtml",
    "datetime": "2020-12-09 11:23:08",
    "code": "002399"
  },
  {
    "title": "海普瑞：公司前三季度国内和欧盟依诺肝素钠制剂销售收入保持快速增长 目前正在准备向美国市场正式供货",
    "href": "http://stock.jrj.com.cn/2020/12/09083231446193.shtml",
    "datetime": "2020-12-09 08:32:21",
    "code": "002399"
  },
  {
    "title": "海普瑞(002399.SZ)拟延长第二期员工持股计划存续期",
    "href": "http://stock.jrj.com.cn/2020/12/04194931410090.shtml",
    "datetime": "2020-12-04 19:49:28",
    "code": "002399"
  },
  {
    "title": "从山东省集采数据预判，海普瑞（002399.SZ）（9989.HK）一致性评价显优势",
    "href": "http://stock.jrj.com.cn/2020/12/03084931397491.shtml",
    "datetime": "2020-12-03 08:49:37",
    "code": "002399"
  },
  {
    "title": "海普瑞：全球疫情没有对公司依诺肝素制剂业务造成重大不利影响",
    "href": "http://stock.jrj.com.cn/2020/11/13184131276827.shtml",
    "datetime": "2020-11-13 18:41:30",
    "code": "002399"
  },
  {
    "title": "海普瑞(002399.SZ)：RVX提交有关关键肾保护及血糖控制市场的新知识产权申请",
    "href": "http://stock.jrj.com.cn/2020/11/12224731270401.shtml",
    "datetime": "2020-11-12 22:47:25",
    "code": "002399"
  },
  {
    "title": "海普瑞：原料药销售业务正在逐步恢复正常",
    "href": "http://stock.jrj.com.cn/2020/11/10165831251868.shtml",
    "datetime": "2020-11-10 16:58:38",
    "code": "002399"
  },
  {
    "title": "海普瑞：原料药出货持续恢复中",
    "href": "http://stock.jrj.com.cn/2020/11/10165631251785.shtml",
    "datetime": "2020-11-10 16:56:13",
    "code": "002399"
  },
  {
    "title": "海普瑞(09989.HK)： 依诺肝素钠注射液领先药物INHIXA取得沙特食药局批准",
    "href": "http://stock.jrj.com.cn/2020/11/04181331215644.shtml",
    "datetime": "2020-11-04 18:13:13",
    "code": "002399"
  },
  {
    "title": "海普瑞：客戶將应其生产需求逐步恢复正常采购",
    "href": "http://stock.jrj.com.cn/2020/11/03181931209561.shtml",
    "datetime": "2020-11-03 18:19:11",
    "code": "002399"
  },
  {
    "title": "海普瑞：但公司将继续努力实现制剂和原料药业务对于经营业绩的双重驱动",
    "href": "http://stock.jrj.com.cn/2020/11/03181731209549.shtml",
    "datetime": "2020-11-03 18:17:38",
    "code": "002399"
  },
  {
    "title": "海普瑞：2020年第三季度业绩增长放缓主要原因是疫情导致客户调整肝素原料药采购节奏",
    "href": "http://stock.jrj.com.cn/2020/11/03181531209542.shtml",
    "datetime": "2020-11-03 18:15:30",
    "code": "002399"
  },
  {
    "title": "海普瑞2020年前三季度净利7.09亿增长5.56% CDMO业务收入持续增长",
    "href": "http://stock.jrj.com.cn/2020/10/30145731175188.shtml",
    "datetime": "2020-10-30 14:57:08",
    "code": "002399"
  },
  {
    "title": "海普瑞（002399.SZ）（9989.HK）拿下全部五个规格依诺肝素注射液该品类首个一致性评价",
    "href": "http://stock.jrj.com.cn/2020/10/27091431139756.shtml",
    "datetime": "2020-10-27 09:14:29",
    "code": "002399"
  },
  {
    "title": "海普瑞：天道医药获准注册为美国市场依诺肝素钠制剂上市许可持有人的供应商，目前正在进行正式供货准备",
    "href": "http://stock.jrj.com.cn/2020/10/23131131115689.shtml",
    "datetime": "2020-10-23 13:11:54",
    "code": "002399"
  },
  {
    "title": "海普瑞（002399.SZ）（9989.HK）：获FDA批准成依诺肝素制剂供应商，美国市场再下一城",
    "href": "http://stock.jrj.com.cn/2020/09/23083630815031.shtml",
    "datetime": "2020-09-23 08:36:24",
    "code": "002399"
  },
  {
    "title": "海普瑞孙公司拟申请6.5亿元综合授信额度 公司将为其提供担保",
    "href": "http://stock.jrj.com.cn/2020/09/18184130778311.shtml",
    "datetime": "2020-09-18 18:41:32",
    "code": "002399"
  },
  {
    "title": "海普瑞：上半年扣非净利同比增长667.76% 制剂业务量价齐升",
    "href": "http://stock.jrj.com.cn/2020/08/30215630624068.shtml",
    "datetime": "2020-08-30 21:56:00",
    "code": "002399"
  },
  {
    "title": "海普瑞2020年上半年净利5.81亿增长6% 肝素产业链受制剂业务驱动业绩快速增长",
    "href": "http://stock.jrj.com.cn/2020/08/30153630622671.shtml",
    "datetime": "2020-08-30 15:36:45",
    "code": "002399"
  },
  {
    "title": "制剂业务量价齐升 海普瑞上半年扣非净利同比增长667.76%",
    "href": "http://stock.jrj.com.cn/2020/08/28221230617038.shtml",
    "datetime": "2020-08-28 22:12:27",
    "code": "002399"
  },
  {
    "title": "肝素板块集体大涨 常山药业、海普瑞、千红制药、汇鸿集团涨停",
    "href": "http://stock.jrj.com.cn/2020/08/07093130447815.shtml",
    "datetime": "2020-08-07 09:31:58",
    "code": "002399"
  },
  {
    "title": "海普瑞港A两地齐大涨！消息称美国启动肝素收储",
    "href": "http://stock.jrj.com.cn/2020/08/06104630439982.shtml",
    "datetime": "2020-08-06 10:46:48",
    "code": "002399"
  },
  {
    "title": "海普瑞2020年上半年预计净利5.46亿元至6.01亿元 毛利率实现大幅上升",
    "href": "http://stock.jrj.com.cn/2020/07/15094130247116.shtml",
    "datetime": "2020-07-15 09:41:41",
    "code": "002399"
  },
  {
    "title": "海普瑞：2020年半年度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2020/07/15082030245656.shtml",
    "datetime": "2020-07-15 08:20:00",
    "code": "002399"
  },
  {
    "title": "海普瑞第一季度盈利2.55亿同比减少49.65% 财务费用增加",
    "href": "http://stock.jrj.com.cn/2020/04/30123129429906.shtml",
    "datetime": "2020-04-30 12:31:31",
    "code": "002399"
  },
  {
    "title": "海普瑞2019年净利10.59亿较上年同期增长79.11% CDMO业务收入同比增长",
    "href": "http://stock.jrj.com.cn/2020/04/29204929423021.shtml",
    "datetime": "2020-04-29 20:49:37",
    "code": "002399"
  },
  {
    "title": "海普瑞：参股子公司拟交易资产并实现资产境外上市",
    "href": "http://stock.jrj.com.cn/2020/04/21090229335763.shtml",
    "datetime": "2020-04-21 09:02:08",
    "code": "002399"
  },
  {
    "title": "早间公告:海普瑞参股子公司拟交易资产并实现资产境外上市",
    "href": "http://stock.jrj.com.cn/2020/04/21082329335464.shtml",
    "datetime": "2020-04-21 08:23:53",
    "code": "002399"
  },
  {
    "title": "早间公告：海普瑞参股子公司拟交易资产并实现资产境外上市",
    "href": "http://stock.jrj.com.cn/2020/04/21081129335431.shtml",
    "datetime": "2020-04-21 08:11:00",
    "code": "002399"
  },
  {
    "title": "海普瑞：赴港IPO获中国证监会核准",
    "href": "http://stock.jrj.com.cn/2020/04/20163929329728.shtml",
    "datetime": "2020-04-20 16:39:00",
    "code": "002399"
  },
  {
    "title": "海普瑞：2020年第一季度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2020/03/29215029136893.shtml",
    "datetime": "2020-03-29 21:50:00",
    "code": "002399"
  },
  {
    "title": "海普瑞2020年一季度预计净利2.5亿元–3亿元 同比下降41%-51%",
    "href": "http://stock.jrj.com.cn/2020/03/29212529136851.shtml",
    "datetime": "2020-03-29 21:25:53",
    "code": "002399"
  },
  {
    "title": "海普瑞：一季度预盈2.5亿元至3亿元",
    "href": "http://stock.jrj.com.cn/2020/03/29170129135992.shtml",
    "datetime": "2020-03-29 17:01:00",
    "code": "002399"
  },
  {
    "title": "海普瑞2019年净利10.8亿增长75.19% 生物制剂CDMO业务增长",
    "href": "http://stock.jrj.com.cn/2020/02/28200628916880.shtml",
    "datetime": "2020-02-28 20:06:46",
    "code": "002399"
  },
  {
    "title": "海普瑞业绩快报：2019年净利润为10.79亿 同比增长75.19%",
    "href": "http://stock.jrj.com.cn/2020/02/28173128915627.shtml",
    "datetime": "2020-02-28 17:31:13",
    "code": "002399"
  },
  {
    "title": "海普瑞向中行申请10亿元内保外贷暨提供反担保",
    "href": "http://stock.jrj.com.cn/2020/02/11211928811405.shtml",
    "datetime": "2020-02-11 21:19:48",
    "code": "002399"
  },
  {
    "title": "[海普瑞]海普瑞捐赠专用药品全力支持抗击新冠病毒肺炎",
    "href": "http://stock.jrj.com.cn/2020/02/06000028785050.shtml",
    "datetime": "2020-02-06 00:00:00",
    "code": "002399"
  },
  {
    "title": "[海普瑞]海普瑞第二届“精英杯”三人制篮球赛圆满结束",
    "href": "http://stock.jrj.com.cn/2020/02/06000028923040.shtml",
    "datetime": "2020-02-06 00:00:00",
    "code": "002399"
  },
  {
    "title": "[海普瑞]海普瑞足球队参加第二届广东生物医药产业技术创新联盟“瀚宇杯”足球争霸赛",
    "href": "http://stock.jrj.com.cn/2020/02/06000028934409.shtml",
    "datetime": "2020-02-06 00:00:00",
    "code": "002399"
  },
  {
    "title": "[海普瑞]深圳市海普瑞药业股份有限公司“研发实验室”获得CNAS实验室认可证书",
    "href": "http://stock.jrj.com.cn/2020/02/06000028932965.shtml",
    "datetime": "2020-02-06 00:00:00",
    "code": "002399"
  },
  {
    "title": "海普瑞：参股公司新药获美国FDA突破性疗法认定",
    "href": "http://stock.jrj.com.cn/2020/02/04155628767414.shtml",
    "datetime": "2020-02-04 15:56:17",
    "code": "002399"
  },
  {
    "title": "[海普瑞]抗击疫情 海普瑞在行动",
    "href": "http://stock.jrj.com.cn/2020/02/03000028758935.shtml",
    "datetime": "2020-02-03 00:00:00",
    "code": "002399"
  },
  {
    "title": "[海普瑞]海普瑞羽毛球队参加第四届“大健康.卫光杯”羽毛球团体赛",
    "href": "http://stock.jrj.com.cn/2020/02/03000028923038.shtml",
    "datetime": "2020-02-03 00:00:00",
    "code": "002399"
  },
  {
    "title": "[海普瑞]RVX-208获得美国FDA突破性疗法认定",
    "href": "http://stock.jrj.com.cn/2020/02/03000028758934.shtml",
    "datetime": "2020-02-03 00:00:00",
    "code": "002399"
  },
  {
    "title": "午间公告：新希望2019年净利预增182%-195%；海普瑞已递交H股上市申请",
    "href": "http://stock.jrj.com.cn/2020/01/23120628727030.shtml",
    "datetime": "2020-01-23 12:06:00",
    "code": "002399"
  },
  {
    "title": "海普瑞：2019年年度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2020/01/23073028725368.shtml",
    "datetime": "2020-01-23 07:30:00",
    "code": "002399"
  },
  {
    "title": "海普瑞2019年度预计净利9.5亿元–11.3亿元 同比增长54%–83%",
    "href": "http://stock.jrj.com.cn/2020/01/22223528723132.shtml",
    "datetime": "2020-01-22 22:35:54",
    "code": "002399"
  },
  {
    "title": "海普瑞2019年预计盈利9.5亿元至11.3亿元",
    "href": "http://stock.jrj.com.cn/2020/01/22213928722894.shtml",
    "datetime": "2020-01-22 21:39:08",
    "code": "002399"
  },
  {
    "title": "海普瑞：预计2019年净利润同比增长54.17%至83.38%",
    "href": "http://stock.jrj.com.cn/2020/01/22201528722591.shtml",
    "datetime": "2020-01-22 20:15:00",
    "code": "002399"
  },
  {
    "title": "海普瑞全年业绩超预期 四季度环比增123.2%-267.3%",
    "href": "http://stock.jrj.com.cn/2020/01/22193728722465.shtml",
    "datetime": "2020-01-22 19:37:00",
    "code": "002399"
  },
  {
    "title": "海普瑞：首次公开发行H股申请材料获中国证监会受理",
    "href": "http://stock.jrj.com.cn/2019/12/27164528597196.shtml",
    "datetime": "2019-12-27 16:45:00",
    "code": "002399"
  },
  {
    "title": "海普瑞：目前原材料采购可以满足正常生产经营需求",
    "href": "http://stock.jrj.com.cn/2019/12/25193028586680.shtml",
    "datetime": "2019-12-25 19:30:00",
    "code": "002399"
  },
  {
    "title": "海普瑞：制剂产品在欧洲销售均价不断提升",
    "href": "http://stock.jrj.com.cn/2019/12/24134628578775.shtml",
    "datetime": "2019-12-24 13:46:00",
    "code": "002399"
  },
  {
    "title": "海普瑞股东乐仁科技质押4360万股 前三季度净利同比增长49%",
    "href": "http://stock.jrj.com.cn/2019/12/20225028564800.shtml",
    "datetime": "2019-12-20 22:50:45",
    "code": "002399"
  },
  {
    "title": "海普瑞三项违规收警示函 董事长李锂及3高管遭监管谈话",
    "href": "http://stock.jrj.com.cn/2019/12/19155928558461.shtml",
    "datetime": "2019-12-19 15:59:00",
    "code": "002399"
  },
  {
    "title": "海普瑞前三季度盈利6.7亿 同比增长49%",
    "href": "http://stock.jrj.com.cn/2019/11/01115528338016.shtml",
    "datetime": "2019-11-01 11:55:34",
    "code": "002399"
  },
  {
    "title": "海普瑞前三季度净利同比增长49% 跨国运营能力突显",
    "href": "http://stock.jrj.com.cn/2019/10/30155328325953.shtml",
    "datetime": "2019-10-30 15:53:33",
    "code": "002399"
  },
  {
    "title": "海普瑞前三季度业绩稳健 跨国运营能力凸显",
    "href": "http://stock.jrj.com.cn/2019/10/29232328320807.shtml",
    "datetime": "2019-10-29 23:23:36",
    "code": "002399"
  },
  {
    "title": "海普瑞：2019年前三季度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2019/10/15091028247731.shtml",
    "datetime": "2019-10-15 09:10:01",
    "code": "002399"
  },
  {
    "title": "海普瑞暴跌背后：新药研发遇挫 成本压力骤升",
    "href": "http://stock.jrj.com.cn/2019/10/15053628246463.shtml",
    "datetime": "2019-10-15 05:36:32",
    "code": "002399"
  },
  {
    "title": "海普瑞净利催肥术：子公司出表增利5.74亿 68亿狂购后资金吃紧40亿短债压身",
    "href": "http://stock.jrj.com.cn/2019/10/14071329218108.shtml",
    "datetime": "2019-10-14 07:13:42",
    "code": "002399"
  },
  {
    "title": "海普瑞净利催肥术：子公司出表增利5.74亿 68亿狂购后资金吃紧40亿短债压身",
    "href": "http://stock.jrj.com.cn/2019/10/14071329375867.shtml",
    "datetime": "2019-10-14 07:13:42",
    "code": "002399"
  },
  {
    "title": "海普瑞净利催肥术：子公司出表增利5.74亿 68亿狂购后资金吃紧40亿短债压身",
    "href": "http://stock.jrj.com.cn/2019/10/14071330152180.shtml",
    "datetime": "2019-10-14 07:13:42",
    "code": "002399"
  },
  {
    "title": "海普瑞净利催肥术：子公司出表增利5.74亿 68亿狂购后资金吃紧40亿短债压身",
    "href": "http://stock.jrj.com.cn/2019/10/14071330502248.shtml",
    "datetime": "2019-10-14 07:13:42",
    "code": "002399"
  },
  {
    "title": "海普瑞净利催肥术：子公司出表增利5.74亿 68亿狂购后资金吃紧40亿短债压身",
    "href": "http://stock.jrj.com.cn/2019/10/14071329952770.shtml",
    "datetime": "2019-10-14 07:13:42",
    "code": "002399"
  },
  {
    "title": "海普瑞净利催肥术：子公司出表增利5.74亿 68亿狂购后资金吃紧40亿短债压身",
    "href": "http://stock.jrj.com.cn/2019/10/14071330276690.shtml",
    "datetime": "2019-10-14 07:13:42",
    "code": "002399"
  },
  {
    "title": "海普瑞净利催肥术：子公司出表增利5.74亿 68亿狂购后资金吃紧40亿短债压身",
    "href": "http://stock.jrj.com.cn/2019/10/14071330453617.shtml",
    "datetime": "2019-10-14 07:13:42",
    "code": "002399"
  },
  {
    "title": "海普瑞上半年利润大增 经营可持续性“注水严重”",
    "href": "http://stock.jrj.com.cn/2019/09/06180328102155.shtml",
    "datetime": "2019-09-06 18:03:01",
    "code": "002399"
  },
  {
    "title": "海普瑞2019年上半年盈利5.5亿 毛利率提升",
    "href": "http://stock.jrj.com.cn/2019/08/27225128043548.shtml",
    "datetime": "2019-08-27 22:51:15",
    "code": "002399"
  },
  {
    "title": "海普瑞审计部负责人达静辞职",
    "href": "http://stock.jrj.com.cn/2019/08/07222327944321.shtml",
    "datetime": "2019-08-07 22:23:14",
    "code": "002399"
  },
  {
    "title": "海普瑞2019年上半年盈利5.25亿元–6.3亿元 同比增长140-188%",
    "href": "http://stock.jrj.com.cn/2019/07/15120327841205.shtml",
    "datetime": "2019-07-15 12:03:38",
    "code": "002399"
  },
  {
    "title": "海普瑞：2019年半年度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2019/07/14215027838576.shtml",
    "datetime": "2019-07-14 21:50:01",
    "code": "002399"
  },
  {
    "title": "海普瑞：控股子公司收到新药III期临床试验通知书",
    "href": "http://stock.jrj.com.cn/2019/07/08191627810564.shtml",
    "datetime": "2019-07-08 19:16:31",
    "code": "002399"
  },
  {
    "title": "海普瑞：孙公司收到波兰药监局GMP证书",
    "href": "http://stock.jrj.com.cn/2019/06/26164227758901.shtml",
    "datetime": "2019-06-26 16:42:49",
    "code": "002399"
  },
  {
    "title": "海普瑞：全资孙公司收到波兰药监局GMP证书",
    "href": "http://stock.jrj.com.cn/2019/06/26155527758699.shtml",
    "datetime": "2019-06-26 15:55:00",
    "code": "002399"
  },
  {
    "title": "海普瑞一季度净利5.07亿元 现金流量净额为-1.38亿元",
    "href": "http://stock.jrj.com.cn/2019/05/06073327526967.shtml",
    "datetime": "2019-05-06 07:33:09",
    "code": "002399"
  },
  {
    "title": "海普瑞去年净利6.16亿同比增213% 董事长李锂薪酬350万元",
    "href": "http://stock.jrj.com.cn/2019/05/04211427521718.shtml",
    "datetime": "2019-05-04 21:14:34",
    "code": "002399"
  },
  {
    "title": "海普瑞一季度净利润同比增长636%",
    "href": "http://stock.jrj.com.cn/2019/04/29182727508592.shtml",
    "datetime": "2019-04-29 18:27:17",
    "code": "002399"
  },
  {
    "title": "深圳支持民企发债千亿计划加快落地 海普瑞发债融资7亿元",
    "href": "http://stock.jrj.com.cn/2019/04/23115727464986.shtml",
    "datetime": "2019-04-23 11:57:19",
    "code": "002399"
  },
  {
    "title": "深圳高新投助力海普瑞债券融资 民企发债千亿专项计划加快落地",
    "href": "http://stock.jrj.com.cn/2019/04/23111127464600.shtml",
    "datetime": "2019-04-23 11:11:00",
    "code": "002399"
  },
  {
    "title": "海普瑞：2019年第一季度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2019/03/29175027267907.shtml",
    "datetime": "2019-03-29 17:50:00",
    "code": "002399"
  },
  {
    "title": "海普瑞一季度净利预增逾10倍",
    "href": "http://stock.jrj.com.cn/2019/03/29163827267328.shtml",
    "datetime": "2019-03-29 16:38:55",
    "code": "002399"
  },
  {
    "title": "海普瑞：一季度预计盈利5亿元同比增逾10倍",
    "href": "http://stock.jrj.com.cn/2019/03/29161527267099.shtml",
    "datetime": "2019-03-29 16:15:14",
    "code": "002399"
  },
  {
    "title": "海普瑞：一季度净利预增逾10倍",
    "href": "http://stock.jrj.com.cn/2019/03/29160427267081.shtml",
    "datetime": "2019-03-29 16:04:00",
    "code": "002399"
  },
  {
    "title": "海普瑞：控股子公司获意大利GMP证书",
    "href": "http://stock.jrj.com.cn/2019/03/13162727160345.shtml",
    "datetime": "2019-03-13 16:27:00",
    "code": "002399"
  },
  {
    "title": "海普瑞：控股子公司成都深瑞畜收到GMP证书",
    "href": "http://stock.jrj.com.cn/2019/03/13162027160260.shtml",
    "datetime": "2019-03-13 16:20:11",
    "code": "002399"
  },
  {
    "title": "海普瑞：第三期员工持股计划完成股票购买 耗资7907万元",
    "href": "http://stock.jrj.com.cn/hotstock/2019/02/04075927019497.shtml",
    "datetime": "2019-02-04 07:59:59",
    "code": "002399"
  },
  {
    "title": "海普瑞：拟推8700万元员工持股计划",
    "href": "http://stock.jrj.com.cn/2018/12/11174325538349.shtml",
    "datetime": "2018-12-11 17:43:00",
    "code": "002399"
  },
  {
    "title": "海普瑞：目前为止没有产品参加国家药品集中招标带量采购",
    "href": "http://stock.jrj.com.cn/2018/12/11150625533550.shtml",
    "datetime": "2018-12-11 15:06:00",
    "code": "002399"
  },
  {
    "title": "海普瑞：子公司新药获得美国FDA快速通道审评资格认定",
    "href": "http://stock.jrj.com.cn/hotstock/2018/11/27080025412000.shtml",
    "datetime": "2018-11-27 08:00:11",
    "code": "002399"
  },
  {
    "title": "海普瑞：子公司新药获美国FDA快速通道审评",
    "href": "http://stock.jrj.com.cn/2018/11/26154725409687.shtml",
    "datetime": "2018-11-26 15:47:00",
    "code": "002399"
  },
  {
    "title": "海普瑞：目前猪疫未对公司原材料来源造成明显影响",
    "href": "http://stock.jrj.com.cn/2018/11/13153725339620.shtml",
    "datetime": "2018-11-13 15:37:00",
    "code": "002399"
  },
  {
    "title": "海普瑞：2018年年度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2018/10/29223025274096.shtml",
    "datetime": "2018-10-29 22:30:00",
    "code": "002399"
  },
  {
    "title": "[海普瑞]海普瑞第二届“精英杯”三人制篮球赛圆满结束",
    "href": "http://stock.jrj.com.cn/2018/10/25000025278043.shtml",
    "datetime": "2018-10-25 00:00:00",
    "code": "002399"
  },
  {
    "title": "[海普瑞]公司参加西丽街道总工会“安全生产竞赛活动”荣获季军",
    "href": "http://stock.jrj.com.cn/2018/10/25000026838068.shtml",
    "datetime": "2018-10-25 00:00:00",
    "code": "002399"
  },
  {
    "title": "[海普瑞]炽热之夏,大爱无阻—我司质量控制部员工鞠元记无私捐献造血干细胞",
    "href": "http://stock.jrj.com.cn/2018/10/25000027914327.shtml",
    "datetime": "2018-10-25 00:00:00",
    "code": "002399"
  },
  {
    "title": "午间公告：海普瑞创新药获FDA快速通道审评资格认定",
    "href": "http://stock.jrj.com.cn/2018/09/27121325143902.shtml",
    "datetime": "2018-09-27 12:13:32",
    "code": "002399"
  },
  {
    "title": "午间公告：海普瑞子公司新药获快速通道审评；山东章鼓遭深交所问询",
    "href": "http://stock.jrj.com.cn/2018/09/27115525143997.shtml",
    "datetime": "2018-09-27 11:55:00",
    "code": "002399"
  },
  {
    "title": "84家药企发布三季报业绩预告 24家预计净利涨幅超50%",
    "href": "http://stock.jrj.com.cn/2018/09/21011425122116.shtml",
    "datetime": "2018-09-21 01:14:18",
    "code": "002399"
  },
  {
    "title": "海普瑞：2018年前三季度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2018/08/28214025015821.shtml",
    "datetime": "2018-08-28 21:40:00",
    "code": "002399"
  },
  {
    "title": "海普瑞上半年净利润同比增逾28倍",
    "href": "http://stock.jrj.com.cn/2018/08/28194525015389.shtml",
    "datetime": "2018-08-28 19:45:06",
    "code": "002399"
  },
  {
    "title": "海普瑞：上半年净利2.2亿元 同比增逾28倍",
    "href": "http://stock.jrj.com.cn/2018/08/28191625015203.shtml",
    "datetime": "2018-08-28 19:16:49",
    "code": "002399"
  },
  {
    "title": "海普瑞上半年净利润同比增逾28倍",
    "href": "http://stock.jrj.com.cn/2018/07/30185224880206.shtml",
    "datetime": "2018-07-30 18:52:13",
    "code": "002399"
  },
  {
    "title": "海普瑞：上半年营收增九成 净利增逾28倍",
    "href": "http://stock.jrj.com.cn/2018/07/30184024880140.shtml",
    "datetime": "2018-07-30 18:40:00",
    "code": "002399"
  },
  {
    "title": "海普瑞：上调上半年业绩预期 净利预增超25倍",
    "href": "http://stock.jrj.com.cn/hotstock/2018/07/05075924772346.shtml",
    "datetime": "2018-07-05 07:59:59",
    "code": "002399"
  },
  {
    "title": "多家公司上半年净利大幅预增",
    "href": "http://stock.jrj.com.cn/2018/07/05030224770399.shtml",
    "datetime": "2018-07-05 03:02:21",
    "code": "002399"
  },
  {
    "title": "海普瑞：上调上半年业绩预期 预计增长25倍-30倍",
    "href": "http://stock.jrj.com.cn/2018/07/04170024768892.shtml",
    "datetime": "2018-07-04 17:00:00",
    "code": "002399"
  },
  {
    "title": "海普瑞大幅上修半年度业绩预告",
    "href": "http://stock.jrj.com.cn/2018/07/04165124768852.shtml",
    "datetime": "2018-07-04 16:51:50",
    "code": "002399"
  },
  {
    "title": "海普瑞：RVX-208三期临床试验将在2019年年底前完成",
    "href": "http://stock.jrj.com.cn/2018/06/22160624716496.shtml",
    "datetime": "2018-06-22 16:06:00",
    "code": "002399"
  },
  {
    "title": "海普瑞：3400万元转让成都海通药业85%股权",
    "href": "http://stock.jrj.com.cn/2018/06/06200024647104.shtml",
    "datetime": "2018-06-06 20:00:00",
    "code": "002399"
  },
  {
    "title": "海普瑞：一季度预盈3500万至5200万元 同比扭亏",
    "href": "http://stock.jrj.com.cn/2018/03/28164524315040.shtml",
    "datetime": "2018-03-28 16:45:00",
    "code": "002399"
  },
  {
    "title": "海普瑞现折价大宗交易 近期股价逆势走高",
    "href": "http://stock.jrj.com.cn/2018/02/07215424081856.shtml",
    "datetime": "2018-02-07 21:54:13",
    "code": "002399"
  },
  {
    "title": "海普瑞：子公司获得在澳大利亚开展临床试验许可",
    "href": "http://stock.jrj.com.cn/2018/01/18161523968574.shtml",
    "datetime": "2018-01-18 16:15:00",
    "code": "002399"
  },
  {
    "title": "海普瑞重组被否昨跌停",
    "href": "http://stock.jrj.com.cn/2017/12/29073223868979.shtml",
    "datetime": "2017-12-29 07:32:38",
    "code": "002399"
  },
  {
    "title": "海普瑞24亿元收购案被否 标的盈利能力成拦路虎",
    "href": "http://stock.jrj.com.cn/2017/12/27195223860023.shtml",
    "datetime": "2017-12-27 19:52:00",
    "code": "002399"
  },
  {
    "title": "海普瑞7年超63亿元扩张路径",
    "href": "http://stock.jrj.com.cn/2017/12/05081923744382.shtml",
    "datetime": "2017-12-05 08:19:07",
    "code": "002399"
  },
  {
    "title": "海普瑞近7倍溢价并购自家公司 利益输送还是看好未来",
    "href": "http://stock.jrj.com.cn/2017/12/02152423731037.shtml",
    "datetime": "2017-12-02 15:24:47",
    "code": "002399"
  },
  {
    "title": "海普瑞拟24亿元收购多普乐 进入低分子肝素领域",
    "href": "http://stock.jrj.com.cn/2017/09/11222523096495.shtml",
    "datetime": "2017-09-11 22:25:56",
    "code": "002399"
  },
  {
    "title": "海普瑞：上半年净利同比下降97%",
    "href": "http://stock.jrj.com.cn/2017/07/28191522814326.shtml",
    "datetime": "2017-07-28 19:15:00",
    "code": "002399"
  },
  {
    "title": "海普瑞：拟收购实控人旗下多普乐实业",
    "href": "http://stock.jrj.com.cn/2017/05/30210622549123.shtml",
    "datetime": "2017-05-30 21:06:23",
    "code": "002399"
  },
  {
    "title": "[海普瑞]深圳市海普瑞药业股份有限公司“研发实验室”获得CNAS实验室认可证书",
    "href": "http://stock.jrj.com.cn/2017/04/24000026838069.shtml",
    "datetime": "2017-04-24 00:00:00",
    "code": "002399"
  },
  {
    "title": "[海普瑞]海普瑞药业2017届校园招聘正式启动",
    "href": "http://stock.jrj.com.cn/2017/03/15000026838066.shtml",
    "datetime": "2017-03-15 00:00:00",
    "code": "002399"
  },
  {
    "title": "海普瑞关联方获得欧盟药政批准",
    "href": "http://stock.jrj.com.cn/2016/10/18160321586030.shtml",
    "datetime": "2016-10-18 16:03:31",
    "code": "002399"
  },
  {
    "title": "[互动]海普瑞：截止8月31日机构户数为750户",
    "href": "http://stock.jrj.com.cn/2016/09/05075921412095.shtml",
    "datetime": "2016-09-05 07:59:23",
    "code": "002399"
  },
  {
    "title": "海普瑞年报拟10转6派6元 净利同比增长71.39%",
    "href": "http://stock.jrj.com.cn/2016/04/25214020877385.shtml",
    "datetime": "2016-04-25 21:40:42",
    "code": "002399"
  },
  {
    "title": "海普瑞：推出10转6派6高送转 有望给股价提供上涨动力",
    "href": "http://stock.jrj.com.cn/2016/02/19182220582802.shtml",
    "datetime": "2016-02-19 18:22:47",
    "code": "002399"
  },
  {
    "title": "海普瑞去年净利润增79.67% 股东提议10转6派6元",
    "href": "http://stock.jrj.com.cn/2016/02/19171420582492.shtml",
    "datetime": "2016-02-19 17:14:47",
    "code": "002399"
  },
  {
    "title": "海普瑞：拟使用9亿购买低风险理财产品",
    "href": "http://stock.jrj.com.cn/hotstock/2015/10/29075919997289.shtml",
    "datetime": "2015-10-29 07:59:59",
    "code": "002399"
  },
  {
    "title": "连续对外投资 海普瑞加快构建生物大分子产业链",
    "href": "http://stock.jrj.com.cn/2015/10/12052919908740.shtml",
    "datetime": "2015-10-12 05:29:24",
    "code": "002399"
  },
  {
    "title": "海普瑞：为全资子公司申请银行贷款提供7.9亿元反担",
    "href": "http://stock.jrj.com.cn/hotstock/2015/09/02080019751041.shtml",
    "datetime": "2015-09-02 08:00:05",
    "code": "002399"
  },
  {
    "title": "海普瑞：拟自有资金150万美元对CDH Avata",
    "href": "http://stock.jrj.com.cn/hotstock/2015/04/08075919070693.shtml",
    "datetime": "2015-04-08 07:59:53",
    "code": "002399"
  },
  {
    "title": "海普瑞：子公司医疗器械产品完成欧盟注册",
    "href": "http://stock.jrj.com.cn/hotstock/2015/01/15075918704727.shtml",
    "datetime": "2015-01-15 07:59:50",
    "code": "002399"
  },
  {
    "title": "海普瑞：拟以1.1亿元购买中信银行理财产品",
    "href": "http://stock.jrj.com.cn/hotstock/2014/12/12075918523649.shtml",
    "datetime": "2014-12-12 07:59:47",
    "code": "002399"
  },
  {
    "title": "海普瑞：拟对CANTEX投资3，000万美元",
    "href": "http://stock.jrj.com.cn/hotstock/2014/11/21075918396082.shtml",
    "datetime": "2014-11-21 07:59:48",
    "code": "002399"
  },
  {
    "title": "海普瑞去年净利下降49% 拟10派3",
    "href": "http://stock.jrj.com.cn/2014/04/17202617065853.shtml",
    "datetime": "2014-04-17 20:26:00",
    "code": "002399"
  },
  {
    "title": "海普瑞一季度净利预降40%–50%",
    "href": "http://stock.jrj.com.cn/2014/04/15121017045277.shtml",
    "datetime": "2014-04-15 12:10:00",
    "code": "002399"
  },
  {
    "title": "海普瑞筹划重大事项今起停牌",
    "href": "http://stock.jrj.com.cn/2013/09/26074715890938.shtml",
    "datetime": "2013-09-26 07:47:01",
    "code": "002399"
  },
  {
    "title": "海普瑞26日起停牌 公司正筹划重大事项",
    "href": "http://stock.jrj.com.cn/2013/09/25195215889167.shtml",
    "datetime": "2013-09-25 19:52:11",
    "code": "002399"
  },
  {
    "title": "海普瑞：澄清利益输送与信息披露质疑",
    "href": "http://stock.jrj.com.cn/hotstock/2013/08/13080015671080.shtml",
    "datetime": "2013-08-13 08:00:15",
    "code": "002399"
  },
  {
    "title": "熊锦秋：从海普瑞神话破灭看该如何重启IPO",
    "href": "http://stock.jrj.com.cn/ipo/2013/07/24140715578648.shtml",
    "datetime": "2013-07-24 14:07:35",
    "code": "002399"
  },
  {
    "title": "海普瑞全年净利持平 现金流锐减9亿元",
    "href": "http://stock.jrj.com.cn/2013/04/12105315222465.shtml",
    "datetime": "2013-04-12 10:53:40",
    "code": "002399"
  },
  {
    "title": "海普瑞火山爆发：深潜的大鲨鱼高盛猛抛近半解禁股",
    "href": "http://stock.jrj.com.cn/2013/01/28074114996714.shtml",
    "datetime": "2013-01-28 07:41:39",
    "code": "002399"
  },
  {
    "title": "海普瑞48亿募资“沉睡”银行吃利息 缺乏明确战略规划",
    "href": "http://stock.jrj.com.cn/2012/11/23050614719676.shtml",
    "datetime": "2012-11-23 05:06:00",
    "code": "002399"
  },
  {
    "title": "海普瑞上市656日遇629个破发 188元只剩19.22元",
    "href": "http://stock.jrj.com.cn/2012/11/12084814658097.shtml",
    "datetime": "2012-11-12 08:48:00",
    "code": "002399"
  },
  {
    "title": "海普瑞项目引发中投深圳投行团队解体 胡长生自扛",
    "href": "http://stock.jrj.com.cn/2012/10/29072414583199.shtml",
    "datetime": "2012-10-29 07:24:39",
    "code": "002399"
  },
  {
    "title": "三药企集体出海 海普瑞购亏损公司股权惹争议",
    "href": "http://stock.jrj.com.cn/2012/10/19024614537669.shtml",
    "datetime": "2012-10-19 02:46:09",
    "code": "002399"
  },
  {
    "title": "多伦多垃圾股资不抵债 海普瑞溢价六成收购",
    "href": "http://stock.jrj.com.cn/2012/10/17021614523741.shtml",
    "datetime": "2012-10-17 02:16:54",
    "code": "002399"
  },
  {
    "title": "分红日放量暴跌 高盛抛售海普瑞套现3.18亿元",
    "href": "http://stock.jrj.com.cn/2012/05/10065013061729.shtml",
    "datetime": "2012-05-10 06:50:19",
    "code": "002399"
  },
  {
    "title": "海普瑞：曾经牛梦 梦难长",
    "href": "http://stock.jrj.com.cn/2012/04/18094112812268.shtml",
    "datetime": "2012-04-18 09:41:00",
    "code": "002399"
  },
  {
    "title": "海普瑞公布分配预案 拟10派6元",
    "href": "http://stock.jrj.com.cn/2012/03/27195212592146.shtml",
    "datetime": "2012-03-27 19:52:28",
    "code": "002399"
  },
  {
    "title": "海普瑞断崖 李锂回首黑色一年半",
    "href": "http://stock.jrj.com.cn/2012/03/05061512401060.shtml",
    "datetime": "2012-03-05 06:15:54",
    "code": "002399"
  },
  {
    "title": "海普瑞去年净利同比减少48%",
    "href": "http://stock.jrj.com.cn/2012/02/18052912280464.shtml",
    "datetime": "2012-02-18 05:29:46",
    "code": "002399"
  },
  {
    "title": "海普瑞和佳隆股份共推股权激励计划",
    "href": "http://stock.jrj.com.cn/2011/12/21085911881690.shtml",
    "datetime": "2011-12-21 08:59:52",
    "code": "002399"
  },
  {
    "title": "393位“老富豪”财富缩水3600亿 海普瑞李锂居首",
    "href": "http://stock.jrj.com.cn/2011/12/16165811852953.shtml",
    "datetime": "2011-12-16 16:58:06",
    "code": "002399"
  },
  {
    "title": "海普瑞执行总经理陈乃康辞职",
    "href": "http://stock.jrj.com.cn/2011/11/30171611687624.shtml",
    "datetime": "2011-11-30 17:16:12",
    "code": "002399"
  },
  {
    "title": "海普瑞前3季净利5.1亿 降46.29%",
    "href": "http://stock.jrj.com.cn/2011/10/18192011325795.shtml",
    "datetime": "2011-10-18 19:20:07",
    "code": "002399"
  },
  {
    "title": "海普瑞：注资子公司 “谨慎推荐”评级",
    "href": "http://stock.jrj.com.cn/hotstock/2011/09/19061411069007.shtml",
    "datetime": "2011-09-19 06:14:16",
    "code": "002399"
  },
  {
    "title": "海普瑞拟增资香港子公司",
    "href": "http://stock.jrj.com.cn/2011/09/15070511040454.shtml",
    "datetime": "2011-09-15 07:05:23",
    "code": "002399"
  },
  {
    "title": "海普瑞神话退去 散户割肉机构套牢市值一年缩水500亿",
    "href": "http://stock.jrj.com.cn/2011/08/23070710818377.shtml",
    "datetime": "2011-08-23 07:07:00",
    "code": "002399"
  },
  {
    "title": "散户割肉机构套牢 海普瑞市值一年缩水500亿",
    "href": "http://stock.jrj.com.cn/2011/08/22112310809115.shtml",
    "datetime": "2011-08-22 11:23:03",
    "code": "002399"
  },
  {
    "title": "海普瑞中期净利3.62亿元",
    "href": "http://stock.jrj.com.cn/2011/08/19075810787172.shtml",
    "datetime": "2011-08-19 07:58:52",
    "code": "002399"
  },
  {
    "title": "海普瑞：上下游扩张 产业链补缺",
    "href": "http://stock.jrj.com.cn/2011/08/12084210718799.shtml",
    "datetime": "2011-08-12 08:42:01",
    "code": "002399"
  },
  {
    "title": "“垄断”终结：海普瑞陷三重困局",
    "href": "http://stock.jrj.com.cn/2011/08/02110210606705.shtml",
    "datetime": "2011-08-02 11:02:00",
    "code": "002399"
  },
  {
    "title": "“唯一FDA认证”丧失 海普瑞成长之路再添堵",
    "href": "http://stock.jrj.com.cn/2011/07/31100810588129.shtml",
    "datetime": "2011-07-31 10:08:19",
    "code": "002399"
  },
  {
    "title": "警示函：保荐148元海普瑞的冒友华王韬被秋后算账",
    "href": "http://stock.jrj.com.cn/2011/07/11062810405556.shtml",
    "datetime": "2011-07-11 06:28:55",
    "code": "002399"
  },
  {
    "title": "海普瑞两保荐人被亮黄牌 或牵出幕后铁三角",
    "href": "http://stock.jrj.com.cn/2011/07/05100410363257.shtml",
    "datetime": "2011-07-05 10:04:32",
    "code": "002399"
  },
  {
    "title": "51亿建生物医药研发制造基地 海普瑞超募资金终有去处",
    "href": "http://stock.jrj.com.cn/2011/06/30100310332451.shtml",
    "datetime": "2011-06-30 10:03:47",
    "code": "002399"
  },
  {
    "title": "海普瑞拟51亿投建生物研发制造基地",
    "href": "http://stock.jrj.com.cn/2011/06/29184610327939.shtml",
    "datetime": "2011-06-29 18:46:18",
    "code": "002399"
  },
  {
    "title": "海普瑞对手常山药业本周五上会",
    "href": "http://stock.jrj.com.cn/ipo/2011/06/22153310269504.shtml",
    "datetime": "2011-06-22 15:33:48",
    "code": "002399"
  },
  {
    "title": "海普瑞39亿闲置资金“睡大觉”",
    "href": "http://stock.jrj.com.cn/2011/05/25081310048435.shtml",
    "datetime": "2011-05-25 08:13:13",
    "code": "002399"
  },
  {
    "title": "王亚伟打新华泰证券和海普瑞损失惨重",
    "href": "http://stock.jrj.com.cn/ipo/2011/05/1710329984154.shtml",
    "datetime": "2011-05-17 10:32:43",
    "code": "002399"
  },
  {
    "title": "海普瑞9000万股限售股6日起流通",
    "href": "http://stock.jrj.com.cn/2011/05/0320209877999.shtml",
    "datetime": "2011-05-03 20:20:02",
    "code": "002399"
  },
  {
    "title": "海普瑞千红制药 一季度末肝素存货大幅下降",
    "href": "http://stock.jrj.com.cn/2011/05/0307139869097.shtml",
    "datetime": "2011-05-03 07:13:35",
    "code": "002399"
  },
  {
    "title": "双汇海普瑞齐跳水背后均现高盛身影",
    "href": "http://stock.jrj.com.cn/2011/05/0214089867065.shtml",
    "datetime": "2011-05-02 14:08:42",
    "code": "002399"
  },
  {
    "title": "双汇海普瑞齐跳水 背后均现高盛身影",
    "href": "http://stock.jrj.com.cn/2011/05/0111489866201.shtml",
    "datetime": "2011-05-01 11:48:14",
    "code": "002399"
  },
  {
    "title": "步行业明星公司海普瑞后尘 常州千红制药首季净利降三成",
    "href": "http://stock.jrj.com.cn/2011/04/2913179859675.shtml",
    "datetime": "2011-04-29 13:17:55",
    "code": "002399"
  },
  {
    "title": "下周解禁市值环比下降七成 高盛减持海普瑞概率大",
    "href": "http://stock.jrj.com.cn/2011/04/2907089855222.shtml",
    "datetime": "2011-04-29 07:08:59",
    "code": "002399"
  },
  {
    "title": "难兄难弟：海普瑞与双汇发展“双跳水”",
    "href": "http://stock.jrj.com.cn/2011/04/2607259819484.shtml",
    "datetime": "2011-04-26 07:25:38",
    "code": "002399"
  },
  {
    "title": "第一高价发行股渐行渐远 海普瑞未来走势不容乐观",
    "href": "http://stock.jrj.com.cn/2011/04/2607189819429.shtml",
    "datetime": "2011-04-26 07:18:54",
    "code": "002399"
  },
  {
    "title": "海普瑞5日连跌三成 53股持续弱势",
    "href": "http://stock.jrj.com.cn/invest/2011/04/2523439818077.shtml",
    "datetime": "2011-04-25 23:43:15",
    "code": "002399"
  },
  {
    "title": "海普瑞：短期有望反弹，中期走势仍不乐观",
    "href": "http://stock.jrj.com.cn/hotstock/2011/04/2308349807431.shtml",
    "datetime": "2011-04-23 08:34:08",
    "code": "002399"
  },
  {
    "title": "海普瑞、汉王科技上演季报地雷秀",
    "href": "http://stock.jrj.com.cn/2011/04/2212039803421.shtml",
    "datetime": "2011-04-22 12:03:19",
    "code": "002399"
  },
  {
    "title": "高成长神话海普瑞开盘跌停",
    "href": "http://stock.jrj.com.cn/2011/04/2010569780280.shtml",
    "datetime": "2011-04-20 10:56:00",
    "code": "002399"
  },
  {
    "title": "一季报低于预期 海普瑞领衔大跌秀",
    "href": "http://stock.jrj.com.cn/2011/04/2009249778235.shtml",
    "datetime": "2011-04-20 09:24:00",
    "code": "002399"
  },
  {
    "title": "海普瑞：全产业链整合加大公司竞争力",
    "href": "http://stock.jrj.com.cn/hotstock/2011/04/2008189777477.shtml",
    "datetime": "2011-04-20 08:18:00",
    "code": "002399"
  },
  {
    "title": "海普瑞公布一季报 净利润下降近四成",
    "href": "http://stock.jrj.com.cn/2011/04/1917309773503.shtml",
    "datetime": "2011-04-19 17:30:30",
    "code": "002399"
  },
  {
    "title": "谁敢120块买海普瑞 陪高盛玩-0.632元成本的游戏",
    "href": "http://stock.jrj.com.cn/2011/04/1810549756158.shtml",
    "datetime": "2011-04-18 10:54:28",
    "code": "002399"
  },
  {
    "title": "海普瑞：调低售价影响利润 致力布局肝素钠全产业链",
    "href": "http://stock.jrj.com.cn/2011/04/1807419752792.shtml",
    "datetime": "2011-04-18 07:41:14",
    "code": "002399"
  },
  {
    "title": "海普瑞拟10转10派20元",
    "href": "http://stock.jrj.com.cn/2011/03/2808009576071.shtml",
    "datetime": "2011-03-28 08:00:13",
    "code": "002399"
  },
  {
    "title": "同行不同利 千红生化毛利率仅海普瑞三成",
    "href": "http://stock.jrj.com.cn/2010/12/0303398700688.shtml",
    "datetime": "2010-12-03 03:39:13",
    "code": "002399"
  },
  {
    "title": "海普瑞：实际控制人李锂夫妇360亿人民币资产成粤首富",
    "href": "http://stock.jrj.com.cn/2010/10/2907348439510.shtml",
    "datetime": "2010-10-29 07:34:28",
    "code": "002399"
  },
  {
    "title": "东方园林海普瑞业绩大增 易方达小幅调仓",
    "href": "http://stock.jrj.com.cn/2010/10/2310218397414.shtml",
    "datetime": "2010-10-23 10:21:26",
    "code": "002399"
  },
  {
    "title": "海普瑞：如何募尽其用超有所值",
    "href": "http://stock.jrj.com.cn/2010/09/1703138190746.shtml",
    "datetime": "2010-09-17 03:13:33",
    "code": "002399"
  },
  {
    "title": "海普瑞等10股入选",
    "href": "http://stock.jrj.com.cn/2010/08/3111288062796.shtml",
    "datetime": "2010-08-31 11:28:46",
    "code": "002399"
  },
  {
    "title": "福布斯发布2010年度股票之选 海普瑞等10股入选",
    "href": "http://stock.jrj.com.cn/hotstock/2010/08/3016358052842.shtml",
    "datetime": "2010-08-30 16:35:51",
    "code": "002399"
  },
  {
    "title": "海普瑞套牢机构1.2亿 华夏广发被套最多",
    "href": "http://stock.jrj.com.cn/2010/08/0606267886125.shtml",
    "datetime": "2010-08-06 06:26:37",
    "code": "002399"
  },
  {
    "title": "海普瑞：中报无人喝彩",
    "href": "http://stock.jrj.com.cn/2010/08/0305037861465.shtml",
    "datetime": "2010-08-03 05:03:10",
    "code": "002399"
  },
  {
    "title": "中报点睛 易方达旗下基金扎堆海普瑞",
    "href": "http://stock.jrj.com.cn/2010/08/0209217853688.shtml",
    "datetime": "2010-08-02 09:21:17",
    "code": "002399"
  },
  {
    "title": "海普瑞：上半年每股收益1.6元",
    "href": "http://stock.jrj.com.cn/2010/08/0208427853130.shtml",
    "datetime": "2010-08-02 08:42:12",
    "code": "002399"
  },
  {
    "title": "海普瑞泡沫真相:白衣骑士赛诺非闪现高盛魅影",
    "href": "http://stock.jrj.com.cn/ipo/2010/07/1611087772483.shtml",
    "datetime": "2010-07-16 11:08:00",
    "code": "002399"
  },
  {
    "title": "明星个股海普瑞 博汇纸业",
    "href": "http://stock.jrj.com.cn/hotstock/2010/07/1009417739426.shtml",
    "datetime": "2010-07-10 09:41:00",
    "code": "002399"
  },
  {
    "title": "海普瑞破发幅度逾两成 10家保险公司折戟打新",
    "href": "http://stock.jrj.com.cn/2010/07/0801377727905.shtml",
    "datetime": "2010-07-08 01:37:46",
    "code": "002399"
  },
  {
    "title": "海普瑞：“难觉察的风险”要降临？",
    "href": "http://stock.jrj.com.cn/2010/07/0606327716296.shtml",
    "datetime": "2010-07-06 06:32:49",
    "code": "002399"
  },
  {
    "title": "海普瑞：上半年预增100%至150%",
    "href": "http://stock.jrj.com.cn/2010/06/1803257633650.shtml",
    "datetime": "2010-06-18 03:25:21",
    "code": "002399"
  },
  {
    "title": "从5亿到752亿：高盛-海普瑞-APP暗筑“铁三角”",
    "href": "http://stock.jrj.com.cn/2010/06/1706087627995.shtml",
    "datetime": "2010-06-17 06:08:00",
    "code": "002399"
  },
  {
    "title": "海普瑞：的FDA认证门三疑点",
    "href": "http://stock.jrj.com.cn/2010/06/0611427585940.shtml",
    "datetime": "2010-06-06 11:42:48",
    "code": "002399"
  },
  {
    "title": "海普瑞：能否持续领先是最大疑问",
    "href": "http://stock.jrj.com.cn/2010/06/0312127574599.shtml",
    "datetime": "2010-06-03 12:12:00",
    "code": "002399"
  },
  {
    "title": "海普瑞：最高发行价是怎样炼成的",
    "href": "http://stock.jrj.com.cn/2010/06/0312057574572.shtml",
    "datetime": "2010-06-03 12:05:00",
    "code": "002399"
  },
  {
    "title": "海普瑞张冠李戴？ 唯一认证再遭质疑",
    "href": "http://stock.jrj.com.cn/2010/05/2602597526961.shtml",
    "datetime": "2010-05-26 02:59:29",
    "code": "002399"
  }
]